A Phase I, Open-label, Two-part Study of the Absorption, Metabolism, Excretion, and the Absolute Bioavailability of [14C]-LY3537982 in Healthy Adult Subjects
Latest Information Update: 10 Nov 2024
At a glance
- Drugs Olomorasib (Primary) ; Olomorasib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 05 Sep 2023 Status changed from not yet recruiting to completed.
- 15 Jun 2023 New trial record